(410 ILCS 416/25)

Sec. 25. Reimbursement requirements; notice.

(a) A reimbursement under the program at a trial site that conducts clinical trials must:

(1) be reviewed and approved by the institutional review board associated with the clinical trial for which the reimbursement is provided; and

(2) comply with applicable federal and State laws.

(b) The independent third-party organization operating the program is not required to obtain approval from an institutional review board with respect to the financial eligibility of a subject who is medically eligible for a clinical trial.

(c) The independent third-party organization operating the program shall provide written notice to a subject on:

(1) the nature, availability, and scope of the ancillary financial support under the program; and

(2) the program's general guidelines on financial eligibility.

(Source: P.A. 103-227, eff. 6-30-23.)